Top View
- Controlled Substances List (Adopted by Alabama State Board of Health on January 20, 2021, Effective January 20, 2021)
- CEDIATM LSD Assay
- 13974/02 JV/Dp 1 DG H II COUNCIL of the EUROPEAN UNION
- Products Issue 1 | 2020 Toxicology New Product Listing
- Comprehensive Forensic Toxicological Analysis of Designer Drugs
- The Development of Microfluidic Devices for the Rapid Isolation And
- List of Scheduling Actions, Controlled Substances And
- The Benzylpiperazine (BZP) / Triflouromethylphenylpiperazine
- 4-Methylpiperazine, a Histamine H4 Receptor Antagonist
- N-BENZYLPIPERAZINE (Street Names: BZP, A2, Legal E Or Legal X) December 2019
- Federal Register/Vol. 86, No. 77/Friday, April 23, 2021/Notices
- 6Ar,9S)-Delta-10-THC 1 Cp-LSD 1-(3-Chloro-4-Fluorophenyl
- Piperazine (TFMPP)
- Designer Amphetamines in Forensic Toxicology Casework
- Laboratory Licensure As of July 2003
- Piperazine Designer Drugs Induce Toxicity in Cardiomyoblast H9c2 Cells Through Mitochondrial Impairment
- NIOSH Method 9106: Methamphetamine and Illicit Drugs, Precursors, and Adulterants on Wipes by Liquid-Liquid Extraction
- Piperazine (‘MT-45’) EMCDDA–Europol Joint Report on a New a New on Report Joint EMCDDA–Europol Psychoactive Substance: 1-Cyclohexyl-4- I Contents 3 I 1
- Drugs of Abuse, a DEA Resource Guide (2020 Edition)
- Recommended Methods for the Identification and Analysis of Piperazines in Seized Materials
- Critical Review Report: DOC (4-Chloro-2,5-Dimethoxyamfetamine)
- Benzylpiperazine (BZP)
- 1-(3-Chlorophenyl)Piperazine (Mcpp) Pre-Review Report
- ALEPH-2, a Suspected Anxiolytic and Putative Hallucinogenic Phenylisopropylamine Derivative, Is A
- BZP Fast Facts
- BZP) and Related Compounds
- A Novel Putative Anxiolytic Agent Lacking Affinity for Benzodiazepine Sites and Serotonin-1A Receptors , ~.__.-~,•.: = - Mastercopv
- Rules and Regulations
- 87(R) Hb 2593
- Controlled Substances List (Adopted by Alabama State Board of Health on January 15, 2020, Effective January 15, 2020)
- Determining the Subjective Effects of TFMPP in Human Males
- Novel Psychoactive Substances (Designer Drugs): Overview and Pharmacology of Modulators of Monoamine Signalling
- Europol–EMCDDA Joint Report on a New Psychoactive Substance: 1-Benzylpiperazine (BZP)
- BZP and TFMPP at a 3 Mg/Kg Dose (1:1 Ratio) Produced Parallel Increases in 5-HT and DA, Mirroring the Results of MDMA
- Drugs and Medical Devices Group
- Piperazine (Mcpp)
- Designer Drug (DD) Abuse in Poland; a Review of the Psychoactive And
- 1540 DOT Number: UN 2579 Date: May 1997 Revision: April 2004